Skip to main content

Research Repository

Advanced Search

Dr AMY FULLER's Outputs (4)

Feasibility of conducting a cohort randomized controlled trial assessing the effectiveness of a nurse-led package of care for knee pain (2023)
Journal Article
Fuller, A., Hall, M., Nomikos, P. A., Millar, B., Ogollah, R., Valdes, A., Greenhaff, P., das Nair, R., Doherty, M., Walsh, D. A., & Abhishek, A. (2024). Feasibility of conducting a cohort randomized controlled trial assessing the effectiveness of a nurse-led package of care for knee pain. Rheumatology, 63(6), 1582-1592. https://doi.org/10.1093/rheumatology/kead432

Objective
To evaluate the feasibility of conducting a cohort randomized controlled trial (RCT) of a nurse-led package of care for knee pain and determining a treatment sequence for use in a future trial.

Methods
This study was an open-label, thr... Read More about Feasibility of conducting a cohort randomized controlled trial assessing the effectiveness of a nurse-led package of care for knee pain.

The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., Fuller, A., Rosenthal, A., Becce, F., Bardin, T., Ea, H. K., Filippou, G., Fitzgerald, J., Iagnocco, A., Lioté, F., McCarthy, G. M., Ramonda, R., Richette, P., Sivera, F., Andres, M., …Choi, H. K. (2023). The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Annals of the Rheumatic Diseases, 82(10), 1248-1257. https://doi.org/10.1136/ard-2023-224575

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develop... Read More about The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., Fuller, A., Rosenthal, A., Becce, F., Bardin, T., Ea, H. K., Filippou, G., FitzGerald, J., Iagnocco, A., Lioté, F., McCarthy, G. M., Ramonda, R., Richette, P., Sivera, F., Andres, M., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective
Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develo... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., Fuller, A., Rosenthal, A., Becce, F., Bardin, T., Ea, H. K., Filippou, G., Fitzgerald, J., Iagnocco, A., Lioté, F., McCarthy, G. M., Ramonda, R., Richette, P., Sivera, F., Andres, M., …Choi, H. K. (2023). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, 75(10), 1703-1713. https://doi.org/10.1002/art.42619

Objective

Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have deve... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.